Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0000899243-19-022590
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-08-29 19:56:38
Reporting Period:
2019-08-27
Accepted Time:
2019-08-29 19:56:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1438133 Tandem Diabetes Care Inc TNDM () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1270735 A Douglas Roeder C/o Delphi Ventures,
63 Bovet Road, Suite 351
San Mateo CA 94402
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-08-27 122,018 $70.10 1,173,628 No 4 S Indirect See Footnote
Common Stock Disposition 2019-08-27 1,191 $70.10 11,460 No 4 S Indirect See Footnote
Common Stock Disposition 2019-08-28 166,704 $70.42 1,006,924 No 4 S Indirect See Footnote
Common Stock Disposition 2019-08-28 1,628 $70.42 9,832 No 4 S Indirect See Footnote
Common Stock Disposition 2019-08-28 16,594 $71.00 990,330 No 4 S Indirect See Footnote
Common Stock Disposition 2019-08-28 162 $71.00 9,670 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2019.
  2. This transaction was executed in multiple trades at prices ranging from $70.00 to $70.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. This transaction was executed in multiple trades at prices ranging from $70.00 to $70.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. This transaction was executed in multiple trades at prices ranging from $71.00 to $71.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  5. The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C. ("DMP"), the general partner of Delphi Ventures VIII, L.P. As a managing member of DMP, the Reporting Person shares voting and investment power over the securities held by Delphi Ventures VIII, L.P. and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Delphi Ventures VIII, L.P., except to the extent of his proportionate pecuniary interest therein.
  6. The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C. ("DMP"), the general partner of Delphi BioInvestments VIII, L.P. As a managing member of DMP, the Reporting Person shares voting and investment power over the securities held by Delphi BioInvestments VIII, L.P. and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Delphi BioInvestments VIII, L.P., except to the extent of his proportionate pecuniary interest therein.